A planned registrational phase III trial of AE 37 in patients with breast cancer.

Trial Profile

A planned registrational phase III trial of AE 37 in patients with breast cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 31 May 2013

At a glance

  • Drugs AE 37 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 31 May 2013 This trial is being prepared as part of a Special Protocol Assessment (SPA) with the US FDA, according to a Generex Biotechnology Corporation media release.
    • 17 Jan 2013 Planned initiation date changed from 1 Jan 2013 to 1 Mar 2013; the FDA will accept submission of a phase III breast cancer trial protocol.
    • 03 Jan 2012 Planned initiation date changed from 1 Jun 2013 to 1 Jun 2012, according to a Generex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top